Navigation Links
EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407
Date:10/7/2007

ug. Results from the study will also help characterize the pharmacodynamic effects on tumor blood flow and potentially identify early signs of objective anti-tumor response as measured by CT scans, MRI or PET, in advanced cancer patients with well vascularized solid tumors.

Mr. Talley continued, "Our advancement of EPC2407 and the regulatory progress we announced earlier this month on Ceplene(TM), demonstrates the opportunities inherent in our pursuit of both early- and late-stage cancer programs, and, when combined with our pipeline of pain candidates, illustrates the long-term potential offered by our company."

About EPC2407

EPC2407 was discovered through EpiCept's Anti-cancer Screening Apoptosis Program (ASAP), a proprietary technology used to rapidly test and generate product candidates for cancer. EPC2407 has shown promising vascular targeting activity with nanomolar potencies of anti-tumor activity in pre-clinical in vitro and in vivo studies. The molecule has been shown to induce tumor cell apoptosis and selectively inhibit growth of proliferating cell lines, including multi-drug resistant cell lines. Murine models of human tumor xenografts demonstrated EPC2407 inhibits growth of established tumors of a number of different cancer types more effectively than the other VDAs tested and was synergistic when used in combination with anticancer agents, such as Cisplatin. EPC2407 is one of two VDA compounds currently in clinical trials discovered through EpiCept's ASAP technology. The second compound, Azixa(TM), is part of the EP90745 series of apoptosis inducers, which was licensed by EpiCept to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.

About EpiCept's ASAP Technology

Cancer cells often exhibit unchecked growth caused by the disabling or absence of the natural process of programmed cell death, which is called apoptosis. Apoptosis is normally triggered to destroy a cell from wi
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BASKING RIDGE, N.J. , Oct. 22, 2014 ... (RMANJ), a world-renowned leader in the field ... more rapid approach to embryonic screening. The research ... American Society for Reproductive Medicine (ASRM) meeting in ... chromosome screening (CCS) and single gene defect (SGD) ...
(Date:10/22/2014)... AVACEN Medical announced today that its AVACEN ... clearance by the U.S. Food and Drug Administration. This ... the Internet for: the temporary relief of joint ... and sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... is a sophisticated medical device incorporating over 3,000 firmware ...
(Date:10/22/2014)... YARDLEY, Pa. , Oct. 22, 2014 /PRNewswire/ ... of their animal health medications, a Global Pharmaceutical ... and Antares serialization technology and turnkey solution to ... Photo - http://photos.prnewswire.com/prnh/20141021/153438 ... The product that was serialized and aggregated by ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... Mesa Laboratories, Inc. (Nasdaq: MLAB ) today announced that ... of the Company,s Board of Directors, effectively immediately. , ... "Paul,s experience and insight have been extremely helpful ... J. Sullivan , President and CEO.  "Paul managed Mesa,s Medical product line ...
... July 8 Roxane Laboratories, Inc. announced today the approval ... by the U.S. Food and Drug Administration.  The product is available ... nationwide. , , , ... Laboratories, Anastrozole Tablets are AB rated to ARIMIDEX® (anastrozole) tablets.  Annual ...
Cached Medicine Technology:Paul D. Duke Resigns From Mesa's Board of Directors 2Roxane Laboratories, Inc. Announces the Launch of Anastrozole Tablets 2Roxane Laboratories, Inc. Announces the Launch of Anastrozole Tablets 3
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
(Date:10/22/2014)... Amy Norton HealthDay Reporter ... remain riveted on the three Ebola cases in Dallas. But, ... health threat to Americans. President Barack Obama on Friday ... the virus, which has infected two Dallas nurses who cared ... at Texas Health Presbyterian Hospital. But the U.S. cases ...
(Date:10/22/2014)... 22, 2014 Hay House is pleased to ... and Upgrade Your Life (Paperback; $10.82) written by the highly ... Recovery. This book is meant to help readers of ... of recovery. , Recovery 2.0 is not the average ... 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... 2014 Healthcare professionals who are ... education at home or on-the-go via laptops, tablets ... brand new, premium Seminar-on-Demand CE courses. The new ... 2,000 hours of CE course offerings, ... experience. With such a diverse library, there’s something ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... , SCOTTSDALE, Ariz., Nov. 12 Healthcare Trust of ... investment trust, announced the execution of a Purchase and ... building located in Spartanburg, South Carolina for approximately $16,250,000. ... number of conditions. , The approximate 108,500 SF Mary ...
... MONTREAL, Nov. 12 The International Peak Performance Symposium ... - Via Scarlatti, 33 (close to Stazione Centrale), Milan ... , The conference will focus on the benefits that ... Peak Performance both in Sports and Business. Modern approaches ...
... found elevated amounts of protein involved in blood-brain barrier ... have a biological effect on the brain, but it,s ... risks, a Swedish medical researcher reports. , Fredrik Soderqvist, ... phone users and discovered they had elevated levels of ...
... that lead to myotonic dystrophy , THURSDAY, Nov. 12 (HealthDay ... pneumonia might serve as an effective treatment against a type ... mice and found that it appears to combat genetic defects ... types of muscular dystrophy. The muscle-wasting condition is also known ...
... Rats fed sugary chow suffered withdrawal when regular meals returned , ... of dieting? Join the club. But new research in rats hints ... as kicking drug addiction. , In the study, rats weaned off ... withdrawing from drugs and alcohol. , Rat brains aren,t the same ...
... ... facility in Lake Success, NY. The facility will house some of the practice’s ... M.D., Neuro-Ophthalmologist Scott Uretsky, M.D., Neuropsychologist Gad E. Klein, Ph.D. and Neurophysiologist Marat ... needs of pediatric patients. , ...
Cached Medicine News:Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 108,500 SF Medical Office Building Located in Spartanburg, South Carolina 2Health News:Peak Performance, Neurofeedback and Biofeedback: New Frontiers of Empowerment From, and In, Sport 2Health News:Wireless Phones Alter Levels of Brain Chemical 2Health News:Study Links Yo-Yo Dieting to Addiction 2Health News:Study Links Yo-Yo Dieting to Addiction 3Health News:Neurological Surgery, P.C., of Long Island, NY, Adds New Specialists and Opens New Flagship Facility in Lake Success, NY 2Health News:Neurological Surgery, P.C., of Long Island, NY, Adds New Specialists and Opens New Flagship Facility in Lake Success, NY 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: